Shukra Pharmaceuticals opened higher at ₹67.28, compared with its previous close of ₹66.47. During today's session, the stock has traded between ₹66.35 and ₹68.04, with an average traded price of ₹66.91. It is currently showing a sideways intraday trend.
An investment of ₹10,000 made 1 year ago in Shukra Pharmaceuticals is now worth
₹ 16,101.00
giving a profit of
₹ 6,101.00 (61.01%)
Note: Past profits do not guarantee future returns.
No analyst rating data available.
Today's Change
+0.22 (+0.33%)
Day High
₹68.04
Day Low
₹66.35
Day Open
₹67.28
Prev Close
₹66.47
Volume
29,46,311
Value Traded
₹19.71 Cr
1W Return
-5.39%
1M Return
23.64%
3M Return
61.01%
6M Return
61.01%
1Y Return
61.01%
Market Cap (₹ Cr.)
2,932
PE Ratio
86.40
PB Ratio
29.15
Dividend Yield
0.02%
ROE
24.54%
ROCE
31.66%
Book Value (₹)
2.28
Face Value (₹)
1.00
EPS (TTM)
0.30
Industry PE
-
Beta
-
Debt to Equity
-
1 Week
-5.39%
6 Week
-
1 Month
23.64%
3 Month
61.01%
9 Month
61.01%
Shukra Pharmaceuticals passes all four resolutions at 33rd AGM
All four resolutions at Shukra Pharmaceuticals' 33rd AGM passed successfully. Final dividend for FY26 approved with 99.9966% votes in favour. Adoption of FY26 audited financial statements cleared with 99.9981% support. Re-appointment of Director Sanskruti Patel passed with 99.8574% majority.
13 days agoShukra Pharmaceuticals shareholders approve name change to Shukra Medtech
Shareholders approved changing the company name to Shukra Medtech Limited. Amendment to the MOA object clause was also passed via postal ballot. Promoters voted in favor of both resolutions with 100% support. Overall approval rate for both resolutions exceeded 99.9%.
13 days agoShukra Pharmaceuticals closes trading window for Q2FY27 results
Trading window closed from October 1, 2026, for Q2FY27 results. Closure lasts until 48 hours after financial results declaration. Applies to promoters, directors, KMPs, and connected persons. Board meeting date for Q2FY27 results to be announced later.
19 days agoShukra Pharmaceuticals issues corrigendum for name change to Shukra Medtech
Issued corrigendum to postal ballot notice for name change to Shukra Medtech Limited. Replaced auditor's certificate to meet SEBI Regulation 45 numerical disclosure norms. New medical technology activity accounts for 51.04% of total assets but zero revenue. Remote e-voting allows shareholders to re-cast votes until September 26, 2026.
21 days agoShukra Pharmaceuticals files notice for September 28 AGM
Shukra Pharmaceuticals files notice for 33rd AGM on September 28, 2026. Meeting to adopt FY26 financials and declare ₹0.01 per share dividend. Ms. Sanskruti Patel seeks re-appointment as Executive Director. Special resolution needed for Mr. Dinesh Chauhan as Independent Director. Book closure period set from September 22 to September 28, 2026.
1mo agoShukra Pharmaceuticals opens postal ballot for name change to Shukra Medtech
Postal ballot for name change to Shukra Medtech opens August 28, 2026. E-voting concludes on September 26, 2026, with results by September 29. Board approved MOA alterations to enable MedTech operations. Independent auditor confirms >50% asset investment in new activity.
1mo ago| Stock | LTP | Change % | Market Cap (Cr.) | PE | 1Y Return |
|---|---|---|---|---|---|
| ₹1,770.70 | +0.61% | ₹4,24,850.24 | 34.83 | +5.97% | |
| ₹9,285.00 | -1.50% | ₹2,46,487.58 | 85.12 | +43.41% | |
| ₹4,642.90 | -0.84% | ₹1,76,600.99 | 82.55 | +31.42% | |
| ₹1,132.50 | -0.17% | ₹1,12,967.31 | 24.74 | +14.00% | |
| ₹2,059.40 | -0.47% | ₹1,11,271.90 | 102.63 | +134.89% | |
| ₹1,329.60 | +1.40% | ₹1,07,412.86 | 31.62 | -14.87% | |
| ₹1,240.00 | +0.86% | ₹1,03,500.36 | 32.26 | -1.93% | |
| ₹2,372.00 | -1.17% | ₹97,974.30 | 47.92 | -3.57% | |
| ₹1,684.60 | -1.31% | ₹96,928.16 | 26.40 | +49.04% | |
| ₹1,953.60 | +0.96% | ₹89,336.17 | 16.03 | -0.29% | |
| ₹2,265.30 | -0.78% | ₹63,932.35 | 35.82 | +16.81% | |
| ₹5,250.00 | +0.86% | ₹62,771.63 | 28.34 | -3.75% |
An investment of ₹10,000 made 1 year ago in Shukra Pharmaceuticals is now worth
₹ 16,101.00
giving a profit of
₹ 6,101.00 (61.01%)
Note: Past profits do not guarantee future returns.
